Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.36 |
| ▸ | CTSS | P25774 | 3/20 | 0.36 |
| ▸ | GLS | O94925 | 9/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2353066 | 0.90 | GLS (0.39) | CTSKCTSSGLSHDAC1SIGMAR1 | |
| SCHEMBL2940407 | 0.88 | PPARG (0.35) | CTSK | |
| SCHEMBL4500607 | 0.84 | PRTN3 (0.47) | — | |
| SCHEMBL2352188 | 0.79 | PRTN3 (0.47) | — | |
| SCHEMBL2355879 | 0.79 | PRTN3 (0.47) | — | |
| SCHEMBL2939670 | 0.78 | PPARG (0.34) | CTSK | |
| SCHEMBL15679519 | 0.77 | MMP2 (0.40) | CTSB | |
| SCHEMBL2350401 | 0.74 | GLS (0.37) | CTSKGLSHDAC1NAMPT | |
| SCHEMBL2356327 | 0.74 | CPB2 (0.42) | — | |
| SCHEMBL2357292 | 0.74 | CPB2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528173-B2 | Plasma carboxypeptidase B inhibitors | SCHERING AKTIENGESELLSHAFT (DE) | 2009-05-05 | — | — | US | claimed |
| US-20060247213-A1 | Plasma carboxypeptidase b inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-11-02 | — | — | US | claimed |
| US-20060234986-A1 | Use of TAFI inhibitors for enhanced myocardial reperfusion and facilitated PCI | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-10-19 | — | — | US | claimed |
| US-20060105995-A1 | TAFI inhibitors and their use to treat pulmonary fibrosis | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-18 | — | — | US | claimed |
| US-20110319366-A1 | Plasma Carboxypeptidase B Inhibitors | BUCKMAN BRAD (US) | 2011-12-29 | — | — | US | disclosed |
| US-8008325-B2 | Plasma carboxypeptidase B inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-30 | — | — | US | disclosed |
| EP-2204373-A1 | Phosphonic acid as Plasma Carboxypeptidase B Inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-07-07 | — | — | EP | disclosed |
| US-7528173-B2 | Plasma carboxypeptidase B inhibitors | SCHERING AKTIENGESELLSHAFT (DE) | 2009-05-05 | — | — | US | disclosed |
| US-20090093520-A1 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | BUCKMAN BRAD | 2009-04-09 | — | — | US | disclosed |
| US-20060247213-A1 | Plasma carboxypeptidase b inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-11-02 | — | — | US | disclosed |
| US-20060234986-A1 | Use of TAFI inhibitors for enhanced myocardial reperfusion and facilitated PCI | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-10-19 | — | — | US | disclosed |
| US-20060105995-A1 | TAFI inhibitors and their use to treat pulmonary fibrosis | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060105995-A1 | TAFI inhibitors and their use to treat pulmonary fibrosis | SERPINB1, TFPI, TFPI2 | CTSK 149/4885CTSS 230/4885GLS 1007/4885 |
| US-20110319366-A1 | Plasma Carboxypeptidase B Inhibitors | CPB1, CPB2, CPA1 | CTSK 118/4885CTSS 76/4885GLS 797/4885 |
| US-20090093520-A1 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | CPB1, CPB2, CPA1 | CTSK 118/4885CTSS 76/4885GLS 797/4885 |
| US-20060234986-A1 | Use of TAFI inhibitors for enhanced myocardial reperfusion and facilitated PCI | TFPI, TFPI2, TNNI3 | CTSK 73/4885CTSS 167/4885GLS 3372/4885 |
| US-20060247213-A1 | Plasma carboxypeptidase b inhibitors | CPB1, CPB2, CPA1 | CTSK 122/4885CTSS 75/4885GLS 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.